Print
|
Close
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
Active:
Yes
Cancer Type:
Multiple Myeloma
NCT ID:
NCT06615479
Trial Phases:
Phase III
Protocol IDs:
CA088-1007 (primary)
NCI-2025-00729
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCI Full Details:
http://clinicaltrials.gov/show/NCT06615479
Summary
The purpose of this study is to compare the efficacy and safety of BMS-986393 versus
standard regimens in adult participants with Relapsed or Refractory and
Lanalidomide-refractory Multiple Myeloma.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.